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EFFECTS ON THE KIDNEY-CLINICAL 
Changes in Renal Function After Liver Transplantation Under FK 506 
J. McCauley. J.J. Fung. S. Todo. A. Jain. P. Oeballi. and T.E. Starzl 
SINCE its introduction into clinical trials. FK 506 has proven to be the most potent oral immunosuppres-
sant available. 1-3 Our previous studies have documented 
the nephrotoxicity of FK 506. and have suggested that a 
reduction in renal blood flow is central to its pathogene-
sis.4.S 
The clinical management has been constantly evolving. 
The starting dosage of FK 506 has gradually decreased and 
the IV infusion was changed from a 4-hour infusion to 
l~-hour infusIOns to attenuate the early perioperative 
nephrotoxicity. We will present. herein. the results of our 
experience with nephrotoxicity during the first year of 
primary hepatic transplantation under FK 506. This repre· 
sents the results of a high·dose period and the steepest 
slope of our learning curve in the use of FK 506. Current 
practices emphasize lower initial doses. lower FK 506 
levels. and progressive dosage reductions. Maintaining the 
optimal drug level which minimizes nephrotoxicity while 
avoiding rejection. will likely be assisted by a computer-
based artificial intelligence program which has only re-
cently been developed at the University of Pittsburgh.1> 
PATIENTS AND METHODS 
All of the 28:! adult patIents receiving onhotopic liver transplants 
at the UniversllY of Pittsburgh between September 1989 and July 
1990 were Included in this study. The immunosuppression sched· 
ules have been published elsewhere. and were under evolution 
during this study. In brief. FK 506 was administered at doses of 
0.075 m!!lkg or 0.15 mg/kg IV over 4 hours. then repeated at 0.075 
mg/kg every I ~ hours until oral conversion was possible. At that 
time patIents received 0.15 mg/kg per day. The oral and I V doses 
frequently overlapped for approximately 24 hours. Prednisone. 
with a 5-day IV burst. was employed in many patients. Others 
received between 200 mg or 20 mg/kg per day as the staning dose. 
Rejection episodes were treated with IV Solumedrol bolus. pred-
nisone recycle. or OKT3. All patients received Bactrim (one 
single-strength tablet tWice per dayl and acyclovir adjusted to 
renal funclion. 
Plasma FK 506 levels were measured by enzyme Immunoassay. 
and done so dally while in hospllu'and during each clinic Visit. 
Standard laboratory studies included serum creatinine (Serl. 
BUN. electrolvtes. liver enzymes. cholesterol. uric acid. magne-
sium. and total protein. among others. Values are expressed as 
mean !: standard deviation. Differences between means were 
deterrntned by Student's I test or analysis of vanance when 
appropnate. 
RESULTS 
The changes in SCr over time are depicted in Fig I. 
Invariably. SCr rose in the perioperative period. The 
change in SCr was generally mild to moderate: 76% of 
patients had values <~Kl mg/dL at 7 days postoperatively. 
Hemodialysis was required for the first time in 43 patients. 
Thirty-two patients were dialyzed within the first 30 days. 
and 11 patients after 30 days (range 38 to S68 days). 
Patients requiring late dialysis were typically recipients of 
multiple liver transplants. septic or developed acute tubu-
lar necrosis (ATN) due to hypotension. or nephrotoxic 
antibiotics. Seventeen patients had either ARF or chronic 
renal failure at the time of transplantation. At latest 
follow·up, one patient requiring dialysis prior to transplan· 
tation is on regular dialysis, and is listed for a cadaveric 
renal transplant: one patient with early renal failure has 
required prolonged dialysis (6 months): and two patients 
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Fig 1. SeR after liver transplantation. Error bars are!: SEM. 
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fig 2. ERPF and GFR in one patient after liver transplantation. 
with late renal failure require regular dialysis. The latter 
two patients had renal insufficiency at the time of trans-
plantation. Mean SCr on postoperative day 450 was 1.6 :t 
0.6 mgldL (Fig 1). 
In selected patients. studies for effective renal plasma 
!low (ERPFl and glomerular filtration rate (GFR) were 
perfonned. Fig 2 illustrates the early changes in one 
patient. In essentially all patients. ERPF and GFR de-
creased in parallel after transplantation. A significant fall in 
GFR without a proponionate decrease in ERPF was seen 
in patients with A TN from other causes. 
Hypomagnesemia was common after transplantation. 
Fig 3 illustrates the percentage of patients with hypo-
magnesemia at selected times after transplantation. Ninety 
days after transplantation. 11.8% of patients had values 
< 1.0 mgldL. The prevalence of hypomagnesemia tended 
to decrease after 60 to 90 days. The hypomagnesemia was 
surprisingly well tolerated. even at levels less than 1.0 
mgldL. No seizures. hypocalcemia. or hypokalemia could 
be attributed to hypomagnesemia. although it may have 
lowered the seizure threshold in several pauents with 
seizures from other causes. 
Hyperkalemia was also a common complication of FK 
S06 therapy. At latest follow-up. SS% of the patients 
require !ludroconisone acetate (F1orineO to control hyper-
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FlO 3. Pereenllge of patJents WIIt'I hypomagnesema (magne-
Sium <'.3 mgtdL). 
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kalemia. These patients have been exquisitely sensitive to 
this agent. Common complications of this therapy. how-
ever. were peripheral edema and worsening hypcnension 
due to sodium and water retention. Two patterns of 
hyperkalemia were seen: ( I) in association with hypcrchlo-
remic metabolic acidosis (type IV RTA): and (2) in asso-
ciation with renal insufficiency without acidosis. 
A very low incidence of hypenension. despite the 
hypenensive stimulus of ftudroconisone. was again appar-
ent. At latest follow-up, 37 patients (16.4%) required 
antihypenensive medication. Of these. 30 (81.1%) require 
only one medication. 6 (16.2%) require two. and I (2.7%) 
requires three medications to control hypenension. Pa-
tients with a previous history of hypenension. although 
nonnotensive immediately prior to transplantation. devel-
oped elevated pressures once hepatic function improved. 
Serum creatinine was also greater in patients with a 
hypenensive history (1.8 :t 1.3 mgldL) than their nor-
motensive counterpans (1.4 :t 0.6 mgldL). P < .OS. 
DISCUSSION 
The nephrotoxicity of FK 506 has been described previ-
ously. The patients reponed in this series represent the 
results of empiric trials of FK S06 drug dosing and an earlier 
practice of maintaining relatively high oral doses months 
after transplantation. During this early learning phase. the 
standard dose and schedule of IV administration has 
changed. and the target FK 506 level has fallen dramatically. 
Although the patients in this series have received what 
will likely come to be regarded as very high doses of FK 
S06. renal function has been relatively well preserved 
compared to published trials with cyclosporine and in the 
randomized controllrial of liver transplants at the Univer-
sity of Pittsburgh. 1 
The mechanism of FK S06 nephrotoxicity is currently 
under exploration. Our studies demonstrate that ERPF 
and GFR both decrease after initiation of FK 506. and 
often parallel changes in FK 506 level-decreasing with 
high levels and increasing with lower levels. No precise 
linear relationship exists for SCr and FK 506 levels. but 
elevations in FK 506 are aSSOCiated with deterioration of 
renal function. Many of the findings of in vitro studies 
reponed are similar to those for CyA. but are usually 
milderK~·Di It is now cenain that the nephrotoxicity of FK 
506 is dose-dependent and measures to decrease the quan-
tity of drug reqUired will improve renal function . 
In the early phases of clinical use. the nephrotoxlCIlV of 
FK 506 has been clearly demonstrated. Although our 
clinical expenence. to date. suggests that FK 506 is 
approximately as nephrotOXIC as CyA when used at max-
imai doses. It is likely that the measures now being planned 
will fL!nher reduce its seventy.7 Among these include. the 
addition of a third drug such as azathioprine or the newer 
agents in this class. This Will likely allow funher reduction 
in FK 506 doses. A novel computer-aSSisted drug prescnp-
tion program is now being developed at the University of 
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Pinsburgh.6 With this system. a user-defined target FK 506 
level will be maintained by dose adjustments which correct 
for drug toxicity. Additional potential areas of study in-
clude direct measures to reduce nephrotoxicity by pre-
operative calcium channel blockade. or prostaglandin ad-
ministration. among others. 
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